Cytek Biosciences, Inc. (CTKB) Misses Q4 EPS by 32c, provides guidance

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q4 EPS of ($0.34), $0.32 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $62.1 million versus the consensus estimate of $57.14 million.

GUIDANCE:

Cytek Biosciences, Inc. sees FY2026 revenue of $205-212 million, versus the consensus of $207.4 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance
• Cytek Biosciences adds cloud analysis tool to its digital platform